Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21


Hiding in Plain Sight: Soluble Immunomodulatory Receptors.

Dahal LN, Schwarz H, Ward FJ.

Trends Immunol. 2018 Sep 5. pii: S1471-4906(18)30150-9. doi: 10.1016/ [Epub ahead of print]


Shaving Is an Epiphenomenon of Type I and II Anti-CD20-Mediated Phagocytosis, whereas Antigenic Modulation Limits Type I Monoclonal Antibody Efficacy.

Dahal LN, Huang CY, Stopforth RJ, Mead A, Chan K, Bowater JX, Taylor MC, Narang P, Chan HTC, Kim JH, Vaughan AT, Forconi F, Beers SA.

J Immunol. 2018 Aug 15;201(4):1211-1221. doi: 10.4049/jimmunol.1701122. Epub 2018 Jul 11.


UC-1V150, a potent TLR7 agonist capable of activating macrophages and potentiating mAb-mediated target cell deletion.

Dahal LN, Gadd A, Edwards AD, Cragg MS, Beers SA.

Scand J Immunol. 2018 Jun;87(6):e12666. doi: 10.1111/sji.12666. Epub 2018 May 6.


Complex Interplay between Epitope Specificity and Isotype Dictates the Biological Activity of Anti-human CD40 Antibodies.

Yu X, Chan HTC, Orr CM, Dadas O, Booth SG, Dahal LN, Penfold CA, O'Brien L, Mockridge CI, French RR, Duriez P, Douglas LR, Pearson AR, Cragg MS, Tews I, Glennie MJ, White AL.

Cancer Cell. 2018 Apr 9;33(4):664-675.e4. doi: 10.1016/j.ccell.2018.02.009. Epub 2018 Mar 22.


New revelations from an old receptor: Immunoregulatory functions of the inhibitory Fc gamma receptor, FcγRIIB (CD32B).

Roghanian A, Stopforth RJ, Dahal LN, Cragg MS.

J Leukoc Biol. 2018 Feb 6. doi: 10.1002/JLB.2MIR0917-354R. [Epub ahead of print] Review.


Antibody Tumor Targeting Is Enhanced by CD27 Agonists through Myeloid Recruitment.

Turaj AH, Hussain K, Cox KL, Rose-Zerilli MJJ, Testa J, Dahal LN, Chan HTC, James S, Field VL, Carter MJ, Kim HJ, West JJ, Thomas LJ, He LZ, Keler T, Johnson PWM, Al-Shamkhani A, Thirdborough SM, Beers SA, Cragg MS, Glennie MJ, Lim SH.

Cancer Cell. 2017 Dec 11;32(6):777-791.e6. doi: 10.1016/j.ccell.2017.11.001. Epub 2017 Nov 30.


The dichotomy of T helper 17 cells in cancer.

Dahal LN.

Nat Rev Immunol. 2017 Sep;17(9):592. doi: 10.1038/nri.2017.93. Epub 2017 Aug 21. No abstract available.


TLR-3/9 Agonists Synergize with Anti-ErbB2 mAb-Letter.

Turaj AH, Dahal LN, Beers SA, Cragg MS, Lim SH.

Cancer Res. 2017 Jun 15;77(12):3376-3378. doi: 10.1158/0008-5472.CAN-17-0412. Epub 2017 Jun 5. No abstract available.


STING Activation Reverses Lymphoma-Mediated Resistance to Antibody Immunotherapy.

Dahal LN, Dou L, Hussain K, Liu R, Earley A, Cox KL, Murinello S, Tracy I, Forconi F, Steele AJ, Duriez PJ, Gomez-Nicola D, Teeling JL, Glennie MJ, Cragg MS, Beers SA.

Cancer Res. 2017 Jul 1;77(13):3619-3631. doi: 10.1158/0008-5472.CAN-16-2784. Epub 2017 May 16.


PI3Kδ inhibition elicits anti-leukemic effects through Bim-dependent apoptosis.

Carter MJ, Cox KL, Blakemore SJ, Turaj AH, Oldham RJ, Dahal LN, Tannheimer S, Forconi F, Packham G, Cragg MS.

Leukemia. 2017 Jun;31(6):1423-1433. doi: 10.1038/leu.2016.333. Epub 2016 Nov 15.


Immunoregulatory soluble CTLA-4 modifies effector T-cell responses in systemic lupus erythematosus.

Dahal LN, Basu N, Youssef H, Khanolkar RC, Barker RN, Erwig LP, Ward FJ.

Arthritis Res Ther. 2016 Aug 4;18:180. doi: 10.1186/s13075-016-1075-1.


Optimising B-cell depletion in autoimmune disease: is obinutuzumab the answer?

Reddy V, Dahal LN, Cragg MS, Leandro M.

Drug Discov Today. 2016 Aug;21(8):1330-8. doi: 10.1016/j.drudis.2016.06.009. Epub 2016 Jun 22. Review.


Development and Characterization of Monoclonal Antibodies Specific for Mouse and Human Fcγ Receptors.

Tutt AL, James S, Laversin SA, Tipton TR, Ashton-Key M, French RR, Hussain K, Vaughan AT, Dou L, Earley A, Dahal LN, Lu C, Dunscombe M, Chan HT, Penfold CA, Kim JH, Potter EA, Mockridge CI, Roghanian A, Oldham RJ, Cox KL, Lim SH, Teige I, Frendéus B, Glennie MJ, Beers SA, Cragg MS.

J Immunol. 2015 Dec 1;195(11):5503-16. doi: 10.4049/jimmunol.1402988. Epub 2015 Oct 28.


FcγR requirements leading to successful immunotherapy.

Dahal LN, Roghanian A, Beers SA, Cragg MS.

Immunol Rev. 2015 Nov;268(1):104-22. doi: 10.1111/imr.12342. Review.


Antagonistic human FcγRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo.

Roghanian A, Teige I, Mårtensson L, Cox KL, Kovacek M, Ljungars A, Mattson J, Sundberg A, Vaughan AT, Shah V, Smyth NR, Sheth B, Chan HT, Li ZC, Williams EL, Manfredi G, Oldham RJ, Mockridge CI, James SA, Dahal LN, Hussain K, Nilsson B, Verbeek JS, Juliusson G, Hansson M, Jerkeman M, Johnson PW, Davies A, Beers SA, Glennie MJ, Frendéus B, Cragg MS.

Cancer Cell. 2015 Apr 13;27(4):473-88. doi: 10.1016/j.ccell.2015.03.005.


Rehabilitation or the death penalty: autoimmune B cells in the dock.

Dahal LN, Cragg MS.

Eur J Immunol. 2015 Mar;45(3):687-91. doi: 10.1002/eji.201545464.


Antigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodies.

Tipton TR, Roghanian A, Oldham RJ, Carter MJ, Cox KL, Mockridge CI, French RR, Dahal LN, Duriez PJ, Hargreaves PG, Cragg MS, Beers SA.

Blood. 2015 Mar 19;125(12):1901-9. doi: 10.1182/blood-2014-07-588376. Epub 2015 Jan 28.


Targeting the alternatively spliced soluble isoform of CTLA-4: prospects for immunotherapy?

Ward FJ, Dahal LN, Khanolkar RC, Shankar SP, Barker RN.

Immunotherapy. 2014;6(10):1073-84. doi: 10.2217/imt.14.73. Review.


Isolation, polarization, and expansion of CD4⁺ helper T cell lines and clones using magnetic beads.

Dahal LN, Barker RN, Ward FJ.

Methods Mol Biol. 2014;1134:237-47. doi: 10.1007/978-1-4939-0326-9_18.


The soluble isoform of CTLA-4 as a regulator of T-cell responses.

Ward FJ, Dahal LN, Wijesekera SK, Abdul-Jawad SK, Kaewarpai T, Xu H, Vickers MA, Barker RN.

Eur J Immunol. 2013 May;43(5):1274-85. doi: 10.1002/eji.201242529. Epub 2013 Mar 6.

Supplemental Content

Loading ...
Support Center